REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – MS patients receiving a disease-modifying therapy (DMT) typically stop treatment or switch medications within a few years of starting treatment, according to a new database analysis of MS patients in British Columbia, Canada (Evans et al. ECTRIMS 2011; abstract P687).